Why has NICE said this?
NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS.
The TNF‑alpha inhibitors listed in the previous section were recommended because the benefits to patients justify their cost.
Golimumab and infliximab were not recommended for severe non‑radiographic axial spondyloarthritis because their 'marketing authorisation', which is normally needed before a drug can be prescribed, does not cover patients with this condition. You can find out more from the Medicines and Healthcare products Regulatory Agency (MHRA).